跳至主要内容
临床试验/NCT03444012
NCT03444012已完成不适用

Non-interventional Prospective Data Collection on Persistence and Adherence on Ticagrelor in ACS Adult Patients in Serbia

AstraZeneca9 个研究点 分布在 1 个国家目标入组 269 人开始时间: 2018年3月5日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
269
试验地点
9
主要终点
duration (number of days) on ticagrelor therapy in patients with acute coronary syndrome

研究概览

简要总结

noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia

研究设计

研究类型
Observational
观察模型
Other
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥ 18 years of age
  • diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated
  • Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation.
  • read and signed the Informed Consent Form

排除标准

  • Any contraindications as per approved SmPC of Brilique
  • Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.

结局指标

主要结局

duration (number of days) on ticagrelor therapy in patients with acute coronary syndrome

时间窗: 1 year (12 months)

次要结局

未报告次要终点

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验